Objective: To assess the sensitivity and specificity of 3D double inversion recovery (DIR) MRI for detecting multiple sclerosis (MS) cortical lesions (CLs) using a direct postmortem MRI to histopathology comparison.
Cortical lesions (CLs) are thought to contribute significantly to disease severity in multiple sclerosis (MS), [1] [2] [3] [4] [5] and dominate disease pathology in the progressive phase. 6 Therefore, reliable in vivo detection of CLs is crucial.
Conventional MRI pulse sequences were found to largely miss cortical MS lesions 7, 8 and even with the use of newer MRI techniques such as fluid-attenuated inversion recovery (FLAIR), 7,9 -11 CL detection remained suboptimal. With the introduction of double inversion recovery (DIR) MRI, which simultaneously suppresses the signals from white matter (WM) and CSF, [12] [13] [14] a substantial increase of MRI-detected CLs in patients with MS was found when compared to more conventional sequences. 15, 16 Subsequently, several cross-sectional and longitudinal DIR studies showed that CLs are associated with increased clinical, especially cognitive, impairment in MS. 4, [17] [18] [19] [20] [21] A drawback of DIR as an imaging technique is its poor signal-to-noise ratio and the presence of flow and pulsation artifacts in 2D sequences. [12] [13] [14] 22 An improvement can be obtained with 3D single-slab methods, although the signal-to-noise ratio generally remains low. 23 Together with regional variations in gray matter (GM) signal intensity 23 this may introduce difficulties when scoring cortical MS lesions. Recently, international consensus recommendations for CL scoring with 3D DIR were introduced, 24 but sensitivity and pathologic specificity of 3D DIR have never been formally assessed by comparison to the gold standard of histopathology.
In the current study we aimed to verify CL scoring on postmortem 3D DIR images by directly comparing them to histopathology. This way, sensitivity and specificity of 3D DIR as a technique could be determined.
METHODS Patients and autopsy. For this study, 40 brain slices of 14 patients with chronic MS were studied after rapid autopsy. Patients' characteristics are shown in table 1. As part of the MS Center Amsterdam autopsy protocol, areas of interest are generally sampled from a maximum of 5 coronally cut brain slices, under guidance of postmortem T2-weighted MRI. 25 As T2-weighted scans are usually not helpful in detecting GM lesions, 7 GM areas of interest were selected randomly from the slices for the current study. A total of 60 cortical areas and 8 deep GM areas were selected and used for further histopathologic examination.
Standard protocol approvals, registrations, and patient consents. Ethics approval was obtained from the institutional ethics review board. Prior to death, all donors were registered at the Netherlands Brain Bank, Amsterdam, the Netherlands, and all donors gave written informed consent for the use of their tissue and medical records for research purposes. Matching and analysis. Cortical and deep GM lesions were scored (in consensus by A.S., S.D.R., and J.J.G.G.) on all 3D DIR and 3D FLAIR images which were viewed in a randomized fashion, and readers were blinded to histopathology and clinical information (i.e., prospective scoring). To avoid bias toward scoring in the sampled areas, CLs were assessed throughout the entire MRI of the brain slices, and thus before matching of selected tissue samples to the postmortem MRI. CLs were defined based on prior experience with scorings of cortical GM lesions in in vivo studies using different magnetic field strengths, 4, 16, 26, 27 and was consistent with the recently published consensus recommendations. 24 Among other points, these guidelines offer a scoring strategy to avoid mistaking CLs for cortical vasculature or artifacts caused by magnetic field inhomogeneities.
Postmortem
For the histopathologic scoring, we classified CLs as mixed WM-GM lesions (type I lesions) or purely intracortical lesions. Intracortical lesions included type II lesions (small, round intracortical lesions), type III or subpial lesions, and type IV lesions, which affect the entire width of the cortex. 28 The pathology reader (E.-J.K.) scored cortical lesion types and numbers in PLPstained tissue sections and was blinded to MRI and clinical data. Deep GM lesions were also scored.
After separate prospective MRI and histopathology scorings, PLP-stained tissue sections were carefully matched to the corresponding plane of the 3D DIR and 3D FLAIR images. Matching was performed as described previously. 29 For an example of successfully matched tissue samples, see figure 1. After the blinded, prospective scoring of the postmortem MRI and the tissue-to-MRI matching, only those lesions that were present in brain areas sampled at autopsy were taken into account, and were used for further (retrospective) analysis. After histopathology scores had been made available to the MRI readers, a second, retrospective, unblinded scoring was performed, within the same areas from which tissue was sampled at autopsy. The sensitivity of the MRI sequences for detecting GM lesions was determined by dividing the number of lesions scored in the prospective or retrospective ratings by the number of lesions assessed on histopathology, times 100%. The specificity of the different MRI 
E) as compared to 3D FLAIR (F). (G-I) Subpial (type III) cortical lesions (indicated by thin line in G and arrowheads in H and I) are slightly more conspicuous on 3D DIR (H) than on 3D FLAIR (I). (J-L) Mixed gray-white matter (type I) lesion (asterisks).
Arrowhead in J-L: an intracortical lesion, which was prospectively scored on 3D DIR (K) and only retrospectively (i.e., with knowledge of histopathology) on 3D FLAIR (L).
II-IV), 23 mixed WM-GM lesions (type I)
, and 13 deep GM lesions. Prospectively, we were able to detect 35 of the in total 198 CLs with 3D DIR MRI. As such, the sensitivity of 3D DIR for CL detection was 18%, which is 1.6-fold higher than the sensitivity of 3D FLAIR. Retrospective scoring improved the sensitivity of 3D DIR for CL detection to 37%, which is 2.0-fold higher than 3D FLAIR. The pathologic specificity for 3D DIR was 90% and for 3D FLAIR 81%. Those scored hyperintensities that were discarded as a GM lesion after comparison with histopathology (i.e., false-positives) later appeared to be explained by either sulci with blood and fluid that had been misinterpreted for superficial lesions in the prospective scoring or by juxtacortical lesions that had been mistaken for type I (mixed WM-GM) lesions. The advantage of 3D DIR compared to 3D FLAIR was most evident for the purely intracortical lesions (type II-III-IV lesions; see panels H, I, K, and L of figure 1) , showing a gain of 129% in the prospective scoring (i.e., 9 lesions more), which increased to 240% (i.e., 36 lesions more) in the retrospective scoring. Note that although the sensitivity for detecting intracortical lesions is enlarged with 3D DIR compared to 3D FLAIR, the majority of the CLs are still missed (figure 2). Mixed (type I) lesions were detected with a slightly higher sensitivity using 3D DIR (83% sensitivity) when compared to 3D FLAIR (65% sensitivity) in the prospective rating, and reached almost equal numbers for 3D DIR and 3D FLAIR in the retrospective scoring (96% sensitivity with 3D DIR vs 91% with 3D FLAIR). In terms of both prospective and retrospective detection of deep GM lesions, 3D DIR showed similar sensitivity compared to 3D FLAIR, confirming previous in vivo results.
27
DISCUSSION Postmortem verification of 3D DIR hyperintensities in the GM of patients with MS has long been unavailable. In the current study, we demonstrated that although 3D DIR does not detect most GM lesions (especially not purely intracortical lesions), it has excellent pathologic specificity and higher sensitivity compared to 3D FLAIR (i.e., a relative gain of 3D DIR over 3D FLAIR in the detection of purely intracortical lesions of up to 240%).
Naturally, the scoring criteria and the images used to define lesions in the GM influence the eventual number of scored lesions. Hence, the results of the present study are especially true for the 3D DIR protocol and the scoring criteria used here. However, for CL identification in the current study, we followed recently proposed CL scoring guidelines of an international panel of experts. 24 Hyperintensities were not excessively scored as CLs, as is proven, e.g., by the low number of false-positive scorings (reflected in high specificity) in our study. The apparent distinction in CL numbers scored prospectively and retrospectively also shows that our scoring was conservative. Prospectively, especially type II intracortical and type III subpial lesions were missed (92% and 93%, respectively), and a considerable portion (more than 2 thirds) of all intracortical lesions were still missed when scored retrospectively.
To explain why some CLs are better visible than others, it is important to understand which specific properties of CLs determine their contrast and therefore their relative (in)visibility on MRI. Several factors are known to be responsible for the low contrast between CLs and surrounding GM, including the generally noninflammatory characteristics of cortical lesions (i.e., no complement deposition, gliosis, or blood-brain barrier disruption), the intrinsically low myelin density in the upper cortical layers, and the small size of CLs. 30 -33 The 3D DIR and 3D FLAIR sequences that were used for the current postmortem study are also used in vivo, and image contrasts are comparable. However, a difficulty in the postmortem setting is that additional artifacts caused by blood and water in the sulci may hamper CL detection. As such, it might well be that the sensitivity of 3D DIR and 3D FLAIR for detecting CLs is slightly higher in the in vivo setting, where these artifactually high signal intensities are adequately suppressed by the inversion pulses. However, the current results cannot lend sufficient force to this expectation.
Unfortunately, as a result of the consensus approach for scoring of CLs that was adopted in this study, an interrater consistency score could not be provided. Furthermore, as sequential imaging on the 2 scanner systems used in this study was not possible due to time constraints and for reasons of decaying tissue quality, putative effects of the different scanner types on the numbers of detected CLs were not explored. These issues should be regarded as limitations of the current work, and will need to be investigated in future studies. Ongoing and future imaging of patients with MS at higher magnetic field strengths may further increase the sensitivity for the detection of GM lesions. 34 This has already been shown by in vivo studies using 3D DIR MRI at 3 T 27 and T2*-weighted imaging at 7 T. 35, 36 However, whether imaging techniques at higher magnetic field strengths also show high(er) pathologic specificity remains to be determined. With 3D DIR being increasingly used for CL detection in MS, and consensus recommendations 24 and postmortem verification of this technique now being available, the need for a standardized acquisition protocol also becomes more pressing, as comparison of CL scores between centers will otherwise remain difficult.
The current postmortem study is the first to verify CLs as scored on 3D DIR in the postmortem setting, by direct comparison to histopathology. It was shown that single-slab 3D DIR has excellent pathologic specificity and a higher sensitivity than 3D FLAIR in detecting CLs in patients with MS. The latter confirms previous in vivo data. 16 These findings now further establish the usefulness of 3D DIR for the MS clinical and research setting, and may be used to further fine-tune the discussion revolving around the imaging of CLs. Specifically, other MRI techniques (e.g., T1-based, phase-sensitive inversion recovery techniques) may now be further investigated to determine their sensitivity for CL detection in MS relative to 3D DIR, and future protocols might also explore the added value of combining sequences to optimally visualize lesions in the GM of patients with MS.
AUTHOR CONTRIBUTIONS
A. Seewann: data collection, study design, and writing the paper. E.-J. Kooi: data collection, study design, and writing the paper. S.D. Roosendaal: data collection and study design. P.J.W. Pouwels: study design, intellectual contributions, and writing the paper. M.P. Wattjes: study design, intellectual contributions, and writing the paper. P. van der Valk: study design, intellectual contributions, and writing the paper. F. Barkhof: Figure 2 Two examples of cortical lesions (CLs) that were not scored on 3D double inversion recovery (DIR) and 3D fluid-attenuated inversion recovery (FLAIR) in the prospective scorings and were also not discriminated in the retrospective phase for different reasons areas affecting all layers of the cerebral cortex; despite this extensive demyelination, the lesion was not scored on the MRI (E, F) during prospective and retrospective scorings, because the subtly increased signal intensity on both 3D DIR and 3D FLAIR throughout the entire cortex (indicated by arrowheads) made the distinction between the signal of the lesion and that of normal cortex nearly impossible. White matter lesions were always readily visible on both MRI sequences (asterisks).
study design, intellectual contributions, and writing the paper. C.H. Polman: study design, intellectual contributions, and writing the paper. J.J.G. Geurts: data collection, study design, and writing the paper, guarantor of study.
